Initiated Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia; Actively Preparing for Commercial Launch Updated Cash Guidance - Sufficient to Fund Operations Through End of ...
PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding ...
NEW ORLEANS, Jan. 14, 2022 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until February 18, 2022 to file lead plaintiff applications in a ...
NEW YORK--(BUSINESS WIRE)--#Pharmaceuticals--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between November 9, 2020 and December 8, ...
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Reata Pharmaceuticals, ...
NEW YORK--(BUSINESS WIRE)--#RETA--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) on behalf ...
NEW YORK--(BUSINESS WIRE)--#RETA--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) on behalf ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Reata Pharmaceuticals, Inc. (“Reata” ...
Copyright © 2015 - 2021 Lifecarenews.in
